baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

C4 Therapeutics/ US12529R1077 /

21/05/2024 21:59:51	Chg. +0.13	Volume	Bid-	Ask-	High	Low
5.75USD	+2.22%	59,037 Turnover: 338,733.36	-Bid Size: -	-Ask Size: -	5.80	5.64

GlobeNewswire 08/05 C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire 29/04 C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 09/04 C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

GlobeNewswire 08/04 C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single...

GlobeNewswire 05/03 C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degra...

GlobeNewswire 04/03 C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...

GlobeNewswire 22/02 C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business High...

GlobeNewswire 09/01 C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted ...

GlobeNewswire 08/01 XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of t...

GlobeNewswire 04/01 C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals

GlobeNewswire 04/01 C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire 12/12/2023 C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple M...

GlobeNewswire 12/12/2023 C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degr...

GlobeNewswire 28/11/2023 C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Re...

GlobeNewswire 20/11/2023 C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

GlobeNewswire 01/11/2023 C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

GlobeNewswire 11/10/2023 C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Deg...

GlobeNewswire 05/09/2023 C4 Therapeutics Announces Chief Financial Officer Succession

GlobeNewswire 16/03/2022 C4 Therapeutics Appoints Utpal Koppikar to Board of Directors

GlobeNewswire 09/03/2022 C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of Soft Tissue S...

GlobeNewswire 08/03/2022 C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 202...

GlobeNewswire 24/02/2022 C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights

GlobeNewswire 10/01/2022 C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation Portfolio

GlobeNewswire 03/01/2022 C4 Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

GlobeNewswire 17/12/2021 C4 Therapeutics Added to NASDAQ Biotechnology Index

C4 Therapeutics/ US12529R1077 /

If you wish to receive reply to your feedback, please provide your email address.